XXXX and risk of @entity1478 : a prospective, comparative study with hormone therapy.

@entity1 @entity172 @entity3556 @entity101 @entity1127 @entity1478 @entity11347
OBJECTIVE: To assess the incidence of @entity1478 during postmenopausal replacement therapy with @entity11347 , using an appropriate control group. DESIGN: A total of 485 postmenopausal @entity1 were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 @entity1 received 2.5 mg/day of @entity11347 and 244 @entity1 served as controls, receiving continuous-combined @entity172 -progestogen therapy ( @entity101 ). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study. RESULTS: Two hundred twenty-one of the @entity1 receiving @entity11347 and 203 receiving continuous-combined @entity101 completed the study. @entity1478 were detected in 74 @entity1 (33.4%) from the @entity11347 group and in 22 @entity1 (10.8%) from the @entity101 group (P < 0.01). The @entity3556 rate did not differ between the groups. The frequency of @entity1127 was significantly higher in the @entity11347 group (P < 0.01). No difference was found in the size of the @entity1127 . CONCLUSIONS: @entity11347 increases by threefold the risk for @entity1478 .
